Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower …

While it is logical to use hypomethylating agents to treat patients with myelodysplastic
syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and …

Hypomethylating agents (HMA) are the first line treatment of higher-risk myelodysplastic
syndromes (MDS) ineligible for bone marrow transplant. Azacitidine (5-azacytine, AZA) …

Patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML)
secondary to MDS may reach complete remission (CR) following intensive chemotherapy …

Hypomethylating agents (HMAs) are the standard of care for higher-risk myelodysplastic
syndrome (MDS) patients in whom azacitidine was the only treatment to demonstrate an …

Background: With the FDA approval of two hypomethylating agents (HA) for the treatment of
myelodysplastic syndromes (MDS), both azacitidine (AZA-C) and decitabine have shown …

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic diseases,
mainly affecting the elderly, characterized by unilinear or multilinear peripheral cytopenia …

Hypomethylating agents (HMAs) have changed the landscape of the management of
patients with higher‐risk myelodysplastic syndromes (HR‐MDS). HMAs have improved …

Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for
myelodysplastic syndrome (MDS). Response to these agents occurs in∼ 50% of treated …

The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the
FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a …